Citations

Clear

107 citation(s) found for "Scheithauer, Bernd".

p53 Expression in Pituitary Adenomas and Carcinomas: Correlation with Invasiveness and Tumor Growth Fractions
Thapar, Kamal, Scheithauer, Bernd W., Kovács, Kálmán, Pernicone, Peter, Laws, Edward R.

Mayo Clinic

Neurosurgery | April 23, 2011 | Volume: 38 | Issue: 4 | Pages: 765-771

10.1227/00006123-199604000-00027 Get It

Meningeal Hemangiopericytoma: Histopathological Features, Treatment, and Long-Term Follow-up of 44 Cases
Guthrie, Barton L. , Ebersold, Michael J., Scheithauer, Bernd W., Shaw, Edward G.

Mayo Clinic

Neurosurgery | April 23, 2011 | Volume: 25 | Issue: 4 | Pages: 514-522

10.1227/00006123-198910000-00003 Get It

Abstract Forty-four cases of meningeal hemangiopericytoma that were treated between 1938 and 1987 are reviewed. Fifty-five percent of these tumors occurred in men. The average age of the patients at diagnosis was 42 years. The average duration of preoperative symptoms was 11 months. Symptoms were related to tumor location, which was similar to that of meningioma. The operative mortality was 9% overall, and has been zero since 1974 (18 patients). The average time before the first recurrence was 47 months, with the recurrence rates at 1, 5, and 10 years after surgery being 15, 65, and 76%, respectively. Ten patients have developed extraneural metastasis, mostly to lung and bone, at an average of 99 months after the first operation. The 10- and 15-year rates of metastasis were 33 and 64%, respectively. The average survival period has been 84 months, with survival rates at 5, 10, and 15 years after surgery of 67, 40, and 23%, respectively. The histological diagnosis of the tumor was not related to survival or recurrence and did not change with recurrence. Tentorial and posterior fossa tumors tended to be more lethal. Total tumor resection favorably affected recurrence and survival, as opposed to subtotal resection. Metastasis adversely affected survival, and was followed by death at an average of 24 months after its diagnosis. Radiation therapy after the first operation extended the average time before first recurrence from 34 to 75 months, and extended survival from 62 to 92 months.
The Effects of Dizocilpine Maleate (MK-801), an Antagonist of the N -Methyl-D-Aspartate Receptor, on Neurologic Recovery and Histopathology following Complete Cerebral Ischemia in Primates
Lanier, William L. , Perkins, William J., Karlsson, Bente R., Milde, James H., Scheithauer, Bernd W., Shearman, Gary T., Michenfelder, John D.

Mayo Clinic

Journal of Cerebral Blood Flow & Metabolism | April 8, 2011 | Volume: 10 | Issue: 2 | Pages: 252-261

10.1038/jcbfm.1990.42 | PMID 2154509 Get It

The present study was designed to determine if the noncompetitive excitatory amino acid antagonist, dizocilpine maleate, when administered after a 17 min period of complete cerebral ischemia in primates, would improve postischemic neurologic function and hippocampal histopathologic outcome when compared to placebo-treated animals. Ten pigtail monkeys were anesthetized and subjected to complete cerebral ischemia using an established neck tourniquet model. Five minutes postischemia, five monkeys received dizocilpine 300 μg/kg i.v. over 5 min, followed by an infusion of 150 μg/kg/h for 10 h. This produced plasma levels of the drug in excess of 30 ng/ml for the duration of the infusion. An additional five monkeys were treated with an identical volume of saline placebo. All monkeys received intensive care for the initial 24 to 48 h postischemia. At 96 h postischemia, there was no significant difference in neurologic function between the two groups ( p = 0.53, with the placebo group having the numerically better outcome). There also was no significant difference between hippocampal histopathology scores between dizocilpine and placebo-treated monkeys. The authors conclude that dizocilpine is not an efficacious therapy in the treatment of neurologic injury that occurs following complete cerebral ischemia in this primate model.
Expression and Distribution of Vascular Endothelial Growth Factor Receptor Flk-1 in the Rat Pituitary
Vidal, Sergio , Lloyd, Ricardo V., Moya, Lucas, Scheithauer, Bernd W., Kovács, Kálmán

Mayo Clinic

Journal of Histochemistry & Cytochemistry | April 1, 2011 | Volume: 50 | Issue: 4 | Pages: 533-540

10.1177/002215540205000410 | PMID 11897806 Get It

Vascular endothelial growth factor (VEGF) acts primarily as an endothelial cell mitogen via the specific receptors Flk-1 and Flt-1. To help further define the possible role of VEGF in the control of pituitary cell function, we examined Flk-1 expression in normal rat pituitaries and in GH3 cells. Flk-1 expression was studied by immunohistochemistry, in situ hybridization, and double-labeling immunofluorescence combined with confocal laser microscopy. In normal rat pituitaries, Flk-1-immunoreactive cells appeared widely distributed only in the anterior lobe and were not detected in the intermediate or posterior lobe. Apart from the adenohypophysial cells, Flk-1 immunopositivity was also evident in endothelial cells of many capillaries distributed throughout the gland. Immunohistochemistry also showed that majority of GH3 cells expressed Flk-1 protein. In situ hybridization showed conclusive staining with the antisense probe and confirmed the immunohistochemical results. The double immunofluorescence method revealed Flk-1 expression in all types of hormone-producing adenohypophysial cells but not in folliculostellate cells. The percentage of immunopositive cells varied among the various cell types. The present study demonstrates that pituitary cells are not only sources of VEGF but also targets of this multifunctional substance, supporting the concept that VEGF functions as an autocrine/paracrine factor in the pituitary.
Subcellular Localization of Leptin in Non-tumorous and Adenomatous Human Pituitaries: An Immuno-ultrastructural Study
Vidal, Sergio , Cohen, Sandra , Horváth, Éva , Kovács, Kálmán, Scheithauer, Bernd W., Burguera, Bartolomé , Lloyd, Ricardo V.

Mayo Clinic

Journal of Histochemistry & Cytochemistry | April 1, 2011 | Volume: 48 | Issue: 8 | Pages: 1147-1152

10.1177/002215540004800811 | PMID 10898807 Get It

Leptin is a key mediator in the maintenance of neuroendocrine homeostasis. Recently, leptin and leptin receptor expression were demonstrated in non-tumorous and adenomatous human pituitaries. This study was performed to determine the subcellular localization of leptin in human adenohypophyses ( n = 3) and in various types of pituitary adenoma ( n = 16). Immunoelectron microscopy showed leptin immunolabeling in most hormone-producing cells of the human non-tumorous adenohypophysis, but not in stellate cells. Labeling was noted over secretory granules. Immunocytochemistry using double labeling revealed leptin expression in GH-, ACTH-, TSH-, and FSH/LH-containing cells but not in PRL cells. The percentage of immunopositive cells and the intensity of immunostaining varied considerably among the various cell types. Immunoelectron microscopy with double gold labeling showed co-localization of leptin and adenohypophysial hormones in the same secretory granules. Among pituitary tumors, leptin immunolabeling was evident only in corticotroph adenomas. Compared to non-tumorous corticotrophs, leptin immunoexpression was less abundant in corticotroph adenomas. The presence of leptin and adenohypophysial hormones in the same secretory granules suggests that leptin is secreted concomitantly with various adenohypophysial hormones and that its release is under the control of hypothalamic stimulating and inhibiting hormones. (J Histochem Cytochem 48:1147–1152, 2000)
Array-Based Comparative Genomic Hybridization Identifies CDK4 and FOXM1 Alterations as Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tum
Yu, Jinsheng , Deshmukh, Hrishikesh , Payton, Jacqueline E. , Scheithauer, Bernd W., Tihan, Tarık , Prayson, Richard A. , Bridge, Julia A. , Ferner, Rosalie E. , Lindberg, Guy, Gutmann, Rebecca J., Emnett, Ryan J., Salavaggione, Lorena, Gutmann, David H. , Nagarajan, Rakesh, Perry, Arie , Dunham, Christopher P. , Guha, Abhijit Ranjan , Watson, Mark A. , Perry, Arie

Mayo Clinic

Clinical Cancer Research | February 16, 2011 | Volume: 17 | Issue: 7 | Pages: 1924-1934

10.1158/1078-0432.ccr-10-1551 | PMID 21325289 Get It

Abstract Purpose: Malignant peripheral nerve sheath tumors (MPNST) are highly aggressive sarcomas with variable patient survival and few known prognostically relevant genomic biomarkers. To identify survival-associated genomic biomarkers, we performed high-resolution array-based comparative genomic hybridization (aCGH) on a large set of MPNSTs. Experimental Design: Candidate gene alterations identified by aCGH in 38 MPNSTs were validated at the DNA, RNA, and protein levels on these same tumors and an independent set of 87 MPNST specimens. Results: aCGH revealed highly complex copy number alterations, including both previously reported and completely novel loci. Four regions of copy number gain were associated with poor patient survival. Candidate genes in these regions include SOX5 (12p12.1), NOL1 and MLF2 (12p13.31), FOXM1 and FKBP1 (12p13.33), and CDK4 and TSPAN31 (12q14.1). Alterations of these candidate genes and several others of interest (ERBB2, MYC and TP53) were confirmed by at least 1 complementary methodology, including DNA and mRNA quantitative real-time PCR, mRNA expression profiling, and tissue microarray-based fluorescence in situ hybridization and immunohistochemistry. Multivariate analysis showed that CDK4 gain/amplification and increased FOXM1 protein expression were the most significant independent predictors for poor survival in MPNST patients (P < 0.05). Conclusions: Our study provides new and independently confirmed candidate genes that could serve as genomic biomarkers for overall survival in MPNST patients. Clin Cancer Res; 17(7); 1924–34. ©2011 AACR.
Cerebellar Pleomorphic Xanthoastrocytoma
Wasdahl, Daniel A., Scheithauer, Bernd W., Jeffrey, Robert A., Andrews, Brian T.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 35 | Issue: 5 | Pages: 947-951

10.1227/00006123-199411000-00022 | PMID 7838347 Get It

Estrogen Receptor Gene Expression in Craniopharyngiomas
Thapar, Kamal, Ştefăneanu, Lucia, Kovács, Kálmán, Scheithauer, Bernd W., Lloyd, Ricardo V., Laws, Edward R. , Müller, Paul J.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 35 | Issue: 6 | Pages: 1012-1017

10.1227/00006123-199412000-00002 | PMID 7885545 Get It

Stereotactic Resection of Juvenile Pilocytic Astrocytomas of the Thalamus and Basal Ganglia
McGirr, Stephen J., Scheithauer, Bernd W., Kelly, Patrick J.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 20 | Issue: 3 | Pages: 447-452

10.1227/00006123-198703000-00016 | PMID 3553982 Get It

Abstract Six patients with juvenile pilocytic astrocytomas of the thalamus or basal ganglia underwent seven computer-assisted stereotactic laser craniotomies with complete or nearly complete removal of the tumor in all cases. The tumor was located in the right basal ganglia in one patient, the left basal ganglia in one patient, and the left thalamus in four patients. Postoperative assessment of the completeness of tumor removal was confirmed by contrast-enhanced computed tomographic scanning within the first 2 weeks after operation. None of the patients was neurologically worse after the procedure, and five were improved. The duration of follow-up ranged from 6 months to 3.5 years. In this group of patients, the computer-assisted, stereotactically guided resection of these deeply located, benign tumors was accomplished with no morbidity or mortality.
Symptomatic Intradural Adrenal Adenoma of the Spinal Nerve Root
Mitchell, Andrew , Scheithauer, Bernd W., Sasano, Hironobu , Hubbard, Elizabeth W. , Ebersold, Michael J.

Mayo Clinic

Neurosurgery | May 30, 2010 | Volume: 32 | Issue: 4 | Pages: 658-662

10.1227/00006123-199304000-00024 | PMID 8474656 Get It